Joint inspections of pharmaceutical supply chains in two Chinese provinces this month are the latest enforcement output of a regulatory system that has been growing more sophisticated – and more punishing – for three consecutive years.
The National Medical Products Administration (NMPA) and the National Healthcare Security Administration (NHSA) launched coordinated inspections of medical institutions and pharmaceutical wholesale enterprises in Inner Mongolia autonomous region and Shanxi province on July 13, acting on leads generated through drug traceability code screenings, according to China Daily. The probe targets irregular traceability records and suspected duplicate reimbursement claims. Any violations will be handled in accordance with applicable law.
Both regions have documented exposure to the fraud typologies regulators are currently targeting. Shanxi’s enforcement history is on record: in August 2025, China Daily reported that a former private hospital controller in Datong, Shanxi, was sentenced to 13 years and six months in prison after orchestrating a scheme involving unnecessary hospitalisations, inflated drug prices, fabricated medical records, and falsified bed occupancy reports that fraudulently claimed more than RMB 9.7 million from the national insurance fund.
The selection of Inner Mongolia reflects a broader structural vulnerability. Research published in Frontiers in Pharmacology in July 2025 identified regional disparities in medical insurance reimbursement policies as creating opportunities for drug arbitrage across China’s economically diverse regions – with drugs purchased cheaply under generous local reimbursement arrangements being resold at higher prices in areas where coverage is limited or absent, fostering a gray market that undermines both drug authenticity and insurance fund sustainability. Inner Mongolia, as a less-developed border region, fits the risk profile regulators have associated with such supply chain diversion.
China’s judiciary has made the consequences explicit. In an August 2025 statement alongside details of four prominent fraud cases, the Supreme People’s Court (SPC) described the national medical insurance fund as people’s “life-saving money,” warning: “The fund concerns the basic interests of the public and relate to the healthy and sustainable development of the medical security system. It is also crucial for the long-term stability of the country.” The court was equally direct about penalties: “For those engaging in fraudulent activities to obtain money from the national medical insurance fund for personal gain and who are seriously undermining the development of the healthcare system, harsh punishments will be imposed.”
The enforcement data across three consecutive years shows a clear trajectory. The NHSA reported in March 2026 that 3,776 cases were jointly investigated with police in 2025, resulting in 10,357 criminal suspects arrested, 1,626 entities verified as having engaged in fraud, and RMB 34.2 billion (US$4.75 billion) in funds recovered. That followed 2024, when US$3.9 billion was recovered – a 47.5% increase over the prior year – with criminal fraud cases rising 131.2% year-on-year. The Supreme People’s Court reported 1,433 criminal cases adjudicated in 2025, implicating 2,807 individuals and representing a 24% year-on-year increase.
The July inspections are the first major provincial-level actions to occur under a materially strengthened regulatory structure that came into force this year. In early 2026, the NHSA issued Implementing Rules for the Regulation on the Supervision of the Use of Medical Insurance Funds, which took effect on April 1. Simultaneously, the NHSA launched a nationwide campaign targeting illegal and irregular practices in the medical insurance and pharmaceutical sector, running in two phases: April to July, and September to November 2026.
The critical new provision is Article 41, which creates a mandatory criminal referral mechanism, requiring medical insurance authorities to refer specified cases to public security organs upon detecting enumerated fraudulent activities. That means entities identified in the Inner Mongolia and Shanxi inspections could face criminal referrals rather than administrative penalties alone – a significant escalation of consequence.
Law firm Hogan Lovells noted in April 2026 that the Implementing Rules and concurrent enforcement campaign “introduce the most operationally detailed medical insurance fraud supervision framework China has seen,” adding that the measures “represent a material increase in risk” for pharmaceutical companies operating in China.
The leads for the current inspections came from traceability code screenings – a detection methodology now embedded directly into the reimbursement system. Since July 1, 2025, prescriptions failing to capture traceability codes have been ineligible for reimbursement. By January 1, 2026, full traceability data collection became mandatory for all designated healthcare providers. The NHSA is deploying intelligent monitoring through the national insurance platform in three phases: 50 key drugs in pilot regions by end of 2025, at least 100 drugs nationwide by mid-2026, and full national standardisation by end of 2026. For insurance professionals, the operational implication is that algorithmic detection – not tip-offs or manual audits – is now the primary trigger for enforcement action across China’s pharmaceutical supply chain. The second phase of the 2026 campaign runs from September to November.
